Unity Biotechnology Inc Reports Results For The Quarter Ended In December: Earnings Summary

Unity Biotechnology

15/04/2024 13:00

* UNITY Biotechnology Inc  UBX.OQ  reported a quarterly
adjusted
loss of 28 cents​​ per share for the quarter ended in December,
higher than the same quarter last year, when the company
reported EPS of $-1.00.  The mean expectation of four analysts
for the quarter was for a loss of 72 cents per share. Wall
Street expected results to range from $-1.15 to -39 cents per
share.
    * Reported revenue was zero​; analysts expected zero. 
    * UNITY Biotechnology Inc's reported EPS for the quarter was
a
loss of 28 cents​.
    * The company reported a quarterly loss of $4.34 million.
    * UNITY Biotechnology Inc shares had fallen by 7.3% this
quarter and lost 21.2% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is  "buy."

Wall Street's median 12-month price target for UNITY
Biotechnology Inc is $6.00 
This summary was machine generated from LSEG data April 15 at
12:00 p.m. UTC. ​All figures in US dollars unless otherwise
stated. (For questions concerning the data in this report,
contact Estimates.Support@lseg.com. For any other questions or
feedback, contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2023      -0.72          -0.28          Beat
 Sep. 30 2023      -0.96          -0.66          Beat
 Jun. 30 2023      -0.86          -0.85          Beat
 Mar. 31 2023      -1.08          -0.76          Beat